News - NMD Pharma
Sep 26, 2023 · NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
NMD Pharma Announces FDA Orphan Drug Designation Granted …
5 days ago · NMD670 is NMD Pharma’s lead development program. It is a first-in-class small molecule inhibitor of the skeletal muscle specific chloride ion channel 1 (CIC-1). NMD Pharma …
Press releases - NMD Pharma
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease
NMD Pharma Announces FDA Orphan Drug Designation Granted …
5 days ago · In November 2024, NMD Pharma announced the initiation of a Phase 2 clinical trial, named SYNAPSE-CMT, of a twice daily oral dose of NMD670 over 21 days in 80 adult …
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b …
Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular …
NMD Pharma Receives IND Clearance from the FDA to initiate a …
Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular …
NMD Pharma Announces Publication of Phase 1 Clinical Trial
Aarhus, Denmark, 19 December 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular …
FDA Approves Phase II Trial of NMD670 for CMT Patients
Jun 18, 2024 · CMTA partner NMD Pharma receives FDA approval for NMD670 Phase II trial in Charcot-Marie-Tooth disease. Learn how it could impact the CMT community.
NMD Pharma Announces FDA Orphan Drug Designation Granted …
5 days ago · “NMD Pharma is committed to addressing the need of patients living with neuromuscular diseases such as CMT, and we are thrilled that the FDA has granted orphan …
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular ...
Sep 26, 2023 · NMD Pharma has pre-clinically demonstrated that ClC-1 inhibition can enhance neuromuscular transmission and ultimately skeletal muscle function in multiple animal models …
- Some results have been removed